There is growing interest in psychedelic compounds such as psilocybin, 3,4-metheylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT) given emerging research on potential uses as treatments for a variety of health conditions. The United States Food and Drug Administration (FDA) has granted multiple “Breakthrough Therapy” designations to various...
Research on Schedule I substances in the United States remains heavily restricted by the regulatory structure imposed by the Controlled Substances Act (CSA). This regulatory system creates significant Research Harm, which can be defined as the restriction or deterrence of legitimate scientific inquiry arising from governmental actions, such as regulatory controls or criminal prohibitions that...